AOD 9604 vs Frag 176-191: What's the Difference?

AOD 9604 and frag 176-191 are not two unrelated peptides. AOD 9604 is a stabilized, modified form of the hGH fragment 176-191, the 16-amino-acid tail of human growth hormone. The practical aod 9604 vs frag 176-191 comparison therefore comes down to stability, research history, and vendor labeling rather than to two different mechanisms. Neither peptide is FDA-approved for weight loss or any other human use in the United States.

What Is HGH Fragment 176-191?

HGH fragment 176-191 is the C-terminal piece of human growth hormone, made up of the final 16 amino acids at positions 176 through 191. Researchers isolated this region because it appears to drive lipolysis, the breakdown of stored fat, without the growth-promoting and blood-sugar effects linked to full-length hGH.

Early rodent studies reported reduced fat mass and inhibited fat storage without raising IGF-1 levels. Human data remain thin, which is one reason the peptide stays a laboratory curiosity rather than a prescribed treatment.

You will also see it written as hGH fragment 176-191, HGH frag 176-191, or simply frag 176-191. All of those names describe the same native 16-amino-acid sequence.

What Is AOD 9604?

AOD 9604, also written AOD-9604 or AOD9604, was developed in the 1990s as a modified version of the same hGH 176-191 region. Chemists added a tyrosine residue at the N-terminus to protect the peptide from rapid enzymatic breakdown, which extended its window of activity in research models.

Because AOD 9604 is a patented analog, it advanced further into human testing than the unmodified fragment did. It reached Phase II human obesity trials, but those studies did not produce a consistent, clinically meaningful weight-loss benefit compared with placebo.

AOD 9604 has also appeared in over-the-counter "HCG diet" drops and similar products that regulators have flagged for deceptive weight-loss claims. AOD 9604 is not an FDA-approved drug, and weight-loss marketing for it is not supported by the clinical trial record.

AOD 9604 vs HGH Frag 176-191: Side-by-Side

The table below summarizes the differences that matter most when researchers compare these two names.

Feature	AOD 9604	HGH Frag 176-191
Structure	Modified hGH 176-191 with an added N-terminal tyrosine	Native hGH C-terminal fragment, residues 176-191
Stability	Engineered for greater resistance to enzymatic degradation	Less stable and faster to degrade in research models
Human research	Reached Phase II obesity trials	Mostly preclinical rodent data
Reported research dose	Commonly cited around 300 mcg once daily	Commonly cited at 250-500 mcg, often two to three times daily
FDA status	Not approved for human use	Not approved for human use
Common labeling	AOD 9604, AOD-9604, AOD9604	HGH frag 176-191, frag 176-191, hGH fragment 176-191

Those dose ranges come from published research summaries and vendor documentation, not from approved prescribing information. No established human dosing standard exists for either peptide.

Do They Work the Same Way?

Both peptides are studied for the same general purpose: stimulating lipolysis and limiting fat storage. The proposed mechanism involves beta-3 adrenergic signaling rather than the growth hormone receptor, which is why researchers expected them to act on fat without raising IGF-1.

That shared mechanism is why the aod 9604 vs hgh frag 176-191 question often comes down to stability rather than biology. If the active region is the same 16-amino-acid sequence, the meaningful difference is how long the molecule survives in the body, not what it does once it arrives.

• AOD 9604 is the more stable analog with more human trial exposure.
• Frag 176-191 is the unmodified parent sequence with primarily animal data.
• Neither has demonstrated reliable fat loss in controlled human trials.

How They Compare With Other Compounds

Researchers rarely stop at aod 9604 vs hgh frag 176-191. The same conversation usually expands to other peptides marketed for metabolic or body-composition research.

Compound	Class	FDA-approved for human use?	Primary research focus
AOD 9604	Modified hGH fragment	No	Lipolysis and fat mass
Frag 176-191	Native hGH fragment	No	Lipolysis and fat mass
Tesamorelin	GHRH analog	Yes, for HIV-associated lipodystrophy	Visceral fat reduction
MOTS-c	Mitochondrial-derived peptide	No	Metabolic regulation
Retatrutide	Triple receptor agonist	No, still investigational	Obesity and type 2 diabetes

The aod 9604 vs tesamorelin comparison is the most striking, because tesamorelin is the only compound in this group with FDA approval, and that approval covers a specific diagnosis rather than general weight loss.

The aod 9604 vs mots-c comparison belongs to metabolic and mitochondrial research rather than fat-loss research. The aod 9604 vs retatrutide comparison is a different category again, since retatrutide is a synthetic triple agonist that targets GLP-1, GIP, and glucagon receptors instead of a growth hormone fragment.

Safety, Sourcing, and Legal Considerations

Peptides sold for "research use only" are not held to the same purity and labeling standards as prescription drugs. Independent testing has repeatedly found that vials labeled as frag 176-191 or AOD 9604 contain incorrect sequences, underdosed material, or fillers.

If you are evaluating either compound for any reason, keep these points in mind:

• AOD 9604 and frag 176-191 are not FDA-approved for human use, and neither is a legal weight-loss treatment.
• Compounding pharmacies cannot dispense them for weight loss under current FDA rules.
• Reported side effects in AOD 9604 human trials were generally mild, but those trials were not designed to detect rare harms.
• Anyone with a metabolic condition, a history of cancer, or who is pregnant or nursing should avoid unapproved peptides entirely.

Talk with a licensed healthcare professional before using any research peptide. A physician can review your history, explain approved alternatives, and monitor for problems that self-directed use tends to miss.

The Bottom Line

AOD 9604 is a modified and more stable version of the hGH fragment 176-191, so the two names describe closely related molecules rather than competing products. AOD 9604 has more human trial data, and that data still fell short of proving meaningful weight loss.

For most people, the most important fact is that neither peptide is FDA-approved for human use in the United States. If fat loss is the goal, evidence-based options reviewed by a physician remain the safer path.

COMMON QUESTIONS

Frequently Asked Questions

Is AOD 9604 the same as HGH frag 176-191?

They are closely related but not identical. AOD 9604 is a modified analog of the hGH fragment 176-191 with an added tyrosine at the N-terminus, while frag 176-191 refers to the native 16-amino-acid C-terminal sequence of human growth hormone. Researchers often group them together, but they are distinct molecules with different stability profiles.

Which is better for fat loss, AOD 9604 or frag 176-191?

Neither peptide is FDA-approved for fat loss, and neither has proven reliable weight-loss benefits in controlled human trials. AOD 9604 has more human data, but it failed to show a consistent advantage over placebo in obesity studies. Frag 176-191 has almost no human data at all, so any fat-loss claim for it is speculative.

Is AOD 9604 legal in the United States?

AOD 9604 is not FDA-approved for human use in the United States. It is sold as a research chemical, and compounding pharmacies cannot legally dispense it for weight loss. Products marketing AOD 9604 with weight-loss claims have drawn regulatory warnings.